CJ-2360

CJ-2360

• CAS Number: 2226742-61-4
• UNSPSC Description: CJ-2360 is a potent and orally active ALK inhibitor with IC50s of 2.2, 4.0, 8.8, 6.3, and 8.9 nM against wild-type ALK and F1197M, G1269A, L1196M, and S1206Y ALK mutants, respectively. CJ-2360 displays potent inhibitory activity against two clinically reported ALK mutants (C1156Y and L1196M) and a few other kinases (LTK, MERTK, CLK1, DAPK1, and DAPK2) among the 468 kinases evaluated[1].
• Target Antigen: Anaplastic lymphoma kinase (ALK)
• Type: Reference compound
• Related Pathways: Protein Tyrosine Kinase/RTK
• Applications: Cancer-Kinase/protease
• Field of Research: Cancer
• Assay Protocol: https://www.medchemexpress.com/cj-2360.html
• Solubility: 10 mM in DMSO
• Smiles: N#CC1=CC(N2)=C(C3=C2N(C(C)C)C4=C(C=C(OC)C(N5C[C@H](C)N(C)[C@H](C)C5)=C4F)C3=O)C=C1
• Molecular Weight: 475.56
• References & Citations: [1]Chen J, et al. Discovery of CJ-2360 as a Potent and Orally Active Inhibitor of Anaplastic Lymphoma Kinase Capable of Achieving Complete Tumor Regression. J Med Chem. 2020;63(22):13994-14016.
• Shipping Conditions: Room temperature
• Clinical Information: No Development Reported